Free Trial

HUTCHMED (LON:HCM) Shares Pass Above 50 Day Moving Average - Should You Sell?

HUTCHMED logo with Medical background

HUTCHMED (China) Limited (LON:HCM - Get Free Report)'s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 223.02 ($3.05) and traded as high as GBX 227 ($3.10). HUTCHMED shares last traded at GBX 227 ($3.10), with a volume of 27,235 shares changing hands.

HUTCHMED Stock Up 4.1%

The company's fifty day simple moving average is GBX 222.56 and its 200 day simple moving average is GBX 228.48. The company has a current ratio of 2.81, a quick ratio of 2.97 and a debt-to-equity ratio of 11.97. The firm has a market capitalization of £2.50 billion, a P/E ratio of -58.70 and a beta of 0.76.

About HUTCHMED

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).

Read More

Should You Invest $1,000 in HUTCHMED Right Now?

Before you consider HUTCHMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.

While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines